drugset / Trial / NCT00003758

Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia

NCT00003758

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of cytarabine plus idarubicin in treating patients who have relapsed acute myelogenous leukemia.

Timeline

Start
1998-12
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule Intravenous
Subject Idarubicin Small molecule Intravenous

Indications